Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (34) 34
index medicus (27) 27
male (27) 27
female (25) 25
life sciences (24) 24
middle aged (24) 24
hematology (21) 21
aged (20) 20
adult (19) 19
cancer (13) 13
transplantation (12) 12
analysis (11) 11
retrospective studies (11) 11
stem cells (11) 11
hematopoietic stem cell transplantation (10) 10
oncology (10) 10
transplantation, homologous (10) 10
treatment outcome (10) 10
chemotherapy (9) 9
immunology (9) 9
leukemia (9) 9
mortality (9) 9
prognosis (9) 9
recurrence (9) 9
transplantation conditioning - methods (9) 9
young adult (9) 9
adolescent (8) 8
disease-free survival (7) 7
hematopoietic stem cells (7) 7
human health and pathology (7) 7
medicine & public health (7) 7
[sdv.can]life sciences [q-bio]/cancer (6) 6
adults (6) 6
bone marrow (6) 6
follow-up studies (6) 6
mesh : female (6) 6
mesh : humans (6) 6
mesh : male (6) 6
mutation (6) 6
survival analysis (6) 6
acute myeloid leukemia (5) 5
aml (5) 5
anesthesiology (5) 5
antineoplastic agents (5) 5
emergency medicine (5) 5
france (5) 5
intensive / critical care medicine (5) 5
leukemia, myeloid, acute - mortality (5) 5
mesh : aged (5) 5
mesh: aged (5) 5
mesh: female (5) 5
mesh: humans (5) 5
mesh: male (5) 5
risk (5) 5
survival rate (5) 5
transplants & implants (5) 5
versus-host-disease (5) 5
[ sdv.imm ] life sciences [q-bio]/immunology (4) 4
abridged index medicus (4) 4
aged, 80 and over (4) 4
antineoplastic agents - therapeutic use (4) 4
blood (4) 4
clinical trials (4) 4
hematology, oncology and palliative medicine (4) 4
lymphocytes (4) 4
medicine, general & internal (4) 4
mesh: middle aged (4) 4
morbidity (4) 4
multivariate analysis (4) 4
myelodysplastic syndrome (4) 4
registries (4) 4
research (4) 4
risk factors (4) 4
therapy (4) 4
tissue donors (4) 4
[ sdv.can ] life sciences [q-bio]/cancer (3) 3
age factors (3) 3
antimitotic agents (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cohort studies (3) 3
critical care medicine (3) 3
daunorubicin (3) 3
expression (3) 3
hematopoietic stem cell transplantation - adverse effects (3) 3
immunotherapy (3) 3
incidence (3) 3
leukemia, myeloid, acute - diagnosis (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, acute - therapy (3) 3
lymphomas (3) 3
medical research (3) 3
medicine, experimental (3) 3
meeting abstracts (3) 3
mesh : aged, 80 and over (3) 3
mesh : hematopoietic stem cell transplantation (3) 3
mesh : middle aged (3) 3
mesh : retrospective studies (3) 3
mesh : survival rate (3) 3
mesh: hematopoietic stem cell transplantation (3) 3
mesh: prognosis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text French Intensive Care Society, International congress – Réanimation 2016
by Jaillette, Emmanuelle and Girault, Christophe and Brunin, Guillaume and Zerimech, Farid and Chiche, Arnaud and Broucqsault-Dedrie, Céline and Fayolle, Cyril and Minacori, Franck and Alves, Isabelle and Barrailler, Stephanie and Robriquet, Laurent and Delaporte, Emmanuel and Thellier, Damien and Delcourte, Claire and Duhamel, Alain and Nseir, Saad and Valette, Xavier and Desmeulles, Isabelle and Savary, Benoit and Masson, Romain and Seguin, Amélie and Daubin, Cédric and Sauneuf, Bertrand and Verrier, Pierre and Pottier, Véronique and Orabona, Marie and Samba, Désiré and Viquesnel, Gérald and Lermuzeaux, Mathilde and Hazera, Pascal and Hanouz, Jean-Luc and Parienti, Jean-Jacques and Du Cheyron, Damien and Demoule, Alexandre and Clavel, Marc and Rolland-Debord, Camille and Perbet, Sébastien and Terzi, Nicolas and Kouatchet, Achille and Wallet, Florent and Roze, Hadrien and Vargas, Frédéric and Guérin, Claude and Dellamonica, Jean and Jaber, Samir and Similowski, Thomas and Quenot, Jean-Pierre and Binquet, Christine and Vinsonneau, Christophe and Barbar, Saber-Davide and Vinault, Sandrine and Deckert, Valérie and Lemaire, Stephanie and Hssain, Ali Ait and Bruyère, Rémi and Souweine, Bertrand and Lagrost, Laurent and Adrie, Christophe and Jung, Boris and Daurat, Aurelien and De Jong, Audrey and Chanques, Gérald and Mahul, Martin and Monnin, Marion and Molinari, Nicolas and Lheureux, Olivier and Trepo, Eric and Hites, Maya and Cotton, Frederic and Wolff, Fleur and Surin, Rudy and Créteur, Jacques and Vincent, Jean-Louis and Gustot, Thierry and Jacobs, Frederique and Taccone, Fabio Silvio and Neuville, Mathilde and Timsit, Jean-François and El-Helali, Najoua and Le Monnier, Alban and Magalhaes, Eric and Radjou, Aguila and Smonig, Roland and Soubirou, Jean-François and Voiriot, Guillaume and Sonneville, Romain and Bouadma, Lila and Mourvillier, Bruno and Gélisse, Elodie and Brasseur, Alexandre and Roisin, Sandrine and De Backer, Daniel and Van Ruychevelt, Valerie and Carlier, Eric and Piagnerelli, Michael and Vanhaeverbeek, Michel and Danguy, Christine and Biston, Patrick and Au, Siu-Ming and Begot, Emmanuelle and ... and Qualité et Sécurité des Soins - CBPR-CFAR and Brain Liver Pitié-Salpêtrière Study Group (BLIPS), Paris, France and Working Group on Mechanical Ventilation and Outcomerea Study Group and COCOONs Study Group and Groupe ALIVE and For the GrrrOH: Groupe de recherche en réanimation respiratoire en Onco-Hématologie (Group for Research in Respiratory Intensive Care Onco-Hematology and EPURE Study Group and For the OUTCOMEREA Study Group and For the BIBLIOFLASH Study Group and Groupe de Recherche en Réanimation Respiratoire et Onco-Hematologique (GRRROH) and RETROMARS Study Group and BoReal study group and ABDOMIX Group and Groupe de travail sur la ventilation and Groupe de Recherche en Reanimation Respiratoire du patient d’Onc-hématologie and Groupe RMM and Université Paris 6 —Pierre et Marie Curie and Institut National pour la Santé et la Recherche Médicale, UMRS1158, Paris and Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie and ABLE French Investigators and ENCEPHALITICA Study Group and Septiflux trial Group and CRICS Network and OutcomeRéa and Committee of young intensivists of the French Society for Intensive Care Medicine (FICS) and NutriSIP and CNER DESC réanimation grand ouest and Phase Angle Project Investigators
Annals of Intensive Care, ISSN 2110-5820, 6/2016, Volume 6, Issue S1, pp. 1 - 236
PHYSICIANS ABSTRACTSO1 Impact of tracheal cuff shape on microaspiration of gastric contents in intubated critically ill patients: a multicenter randomized... 
Intensive / Critical Care Medicine | Emergency Medicine | Anesthesiology | Medicine & Public Health
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Proceedings of Réanimation 2017, the French Intensive Care Society International Congress
by Kamilia, Chtara and Regaieg, Kais and Baccouch, Najeh and Chelly, Hedi and Bahloul, Mabrouk and Bouaziz, Mounir and Jendoubi, Ali and Abbes, Ahmed and Belhaouane, Houda and Nasri, Oussama and Jenzri, Layla and Ghedira, Salma and Houissa, Mohamed and Belkadi, Kamal and Harti, Youness and Nsiri, Afak and Khaleq, Khalid and Hamoudi, Driss and Harrar, Rachid and Thieffry, Camille and Wallet, Frédéric and Parmentier-Decrucq, Erika and Favory, Raphaël and Mathieu, Daniel and Poissy, Julien and Lafon, Thomas and Vignon, Philippe and Begot, Emmanuelle and Appert, Alexandra and Hadj, Mathilde and Claverie, Paul and Matt, Morgan and Barraud, Olivier and François, Bruno and Jamoussi, Amira and Jazia, Amira Ben and Marhbène, Takoua and Lakhdhar, Dhouha and Khelil, Jalila Ben and Besbes, Mohamed and Goutay, Julien and Blazejewski, Caroline and Joly-Durand, Isabelle and Pirlet, Isabelle and Weillaert, Marie Pierre and Beague, Sebastien and Aziz, Soufi and Hafiane, Reda and Hattabi, Khalid and Bouhouri, Mohamed Aziz and Hammoudi, Driss and Fadil, Abdelaziz and Harrar, Rachid Al and Zerouali, Khalid and Medhioub, Fatma Kaaniche and Allela, Rania and Algia, Najla Ben and Cherif, Samar and Slaoui, Mohamed Taoufik and Boubia, Souhail and Hafiani, Y and Khaoudi, A and Cherkab, R and Elallam, W and Elkettani, C and Barrou, L and Ridaii, M and Mehdi, Rihi El and Schimpf, Caroline and Mizrahi, Assaf and Pilmis, Benoît and Le Monnier, Alban and Tiercelet, Kelly and Cherin, Mélanie and Bruel, Cédric and Philippart, Francois and Bailly, Sébastien and Lucet, Jc and Lepape, Alain and L’hériteau, François and Aupée, Martine and Bervas, Caroline and Boussat, Sandrine and Berger-Carbonne, Anne and Machut, Anaïs and Savey, Anne and Timsit, Jean-François and Razazi, Keyvan and Rosman, Jérémy and de Prost, Nicolas and Carteaux, Guillaume and Jansen, Chloe and Decousser, Jean Winoc and Brun-Buisson, Christian and Dessap, Armand Mekontso and M’rad, Aymen and Ouali, Zouhour and Barghouth, Manel and Kouatchet, Achille and Mahieu, Rafael and ... and REA‑RAISIN Study group and Clinical Research in Intensive Care and Sepsis (CRICS network) and Sudden Death Expertise Center and OUTCOMEREA study group and Brain Liver Pitié-Salpêtrière Study Group (BLIPS) and for the HYPER2S Investigators and REVA research network and Cubrea network
Annals of Intensive Care, ISSN 2110-5820, 1/2017, Volume 7, Issue S1, pp. 105 - 207
Intensive / Critical Care Medicine | Emergency Medicine | Anesthesiology | Medicine & Public Health
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
by Nicolas Boissel and Olivier Nibourel and Aline Renneville and Claude Gardin and Oumedaly Reman and Nathalie Contentin and Dominique Bordessoule and Cécile Pautas and Thierry de Revel and Bruno Quesnel and Pascal Huchette and Nathalie Philippe and Sandrine Geffroy and Christine Terre and Xavier Thomas and Sylvie Castaigne and Hervé Dombret and Claude Preudhomme
Journal of Clinical Oncology, ISSN 0732-183X, 08/2010, Volume 28, Issue 23, pp. 3717 - 3723
Purpose Recently, whole-genome sequencing in acute myeloid leukemia (AML) identified recurrent isocitrate dehydrogenase enzyme isoform (IDH1) mutations... 
GENE-MUTATIONS | CYTOGENETIC ABNORMALITIES | AML | IDH2 MUTATIONS | ONCOLOGY | FAVORABLE PROGNOSIS | NUCLEOPHOSMIN NPM1 | YOUNGER ADULTS | CEBPA MUTATIONS | HYPOXIA | EXPRESSION | Prevalence | Prognosis | Humans | Middle Aged | Isocitrate Dehydrogenase - genetics | Randomized Controlled Trials as Topic | Young Adult | Adolescent | Adult | Aged | Retrospective Studies | Mutation | Leukemia, Myeloid, Acute - genetics | Protein Isoforms - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
by Castaigne, Sylvie, Prof and Pautas, Cécile, MD and Terré, Christine, MD and Raffoux, Emmanuel, MD and Bordessoule, Dominique, Prof and Bastie, Jean-Noel, Prof and Legrand, Ollivier, Prof and Thomas, Xavier, MD and Turlure, Pascal, MD and Reman, Oumedaly, MD and de Revel, Thierry, Prof and Gastaud, Lauris, MD and de Gunzburg, Noémie, MD and Contentin, Nathalie, MD and Henry, Estelle and Marolleau, Jean-Pierre, Prof and Aljijakli, Ahmad, MD and Rousselot, Philippe, Prof and Fenaux, Pierre, Prof and Preudhomme, Claude, Prof and Chevret, Sylvie, Prof and Dombret, Hervé, Prof and Acute Leukemia French Association
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Summary Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute... 
Internal Medicine | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | THERAPY | MYLOTARG | EFFICACY | RECOMMENDATIONS | SAFETY | INDUCTION | DAUNORUBICIN | IMMUNOCONJUGATE | CHEMOTHERAPY | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Aminoglycosides - adverse effects | Aminoglycosides - therapeutic use | Bone marrow | Chemotherapy | Mutation | Transplants & implants | Toxicity | Drug dosages | Thrombocytopenia | Intravenous administration | Motivation | Antibodies | Clinical trials | Platelets | Gemtuzumab ozogamicin | Survival | Antineoplastic Agents | Aminoglycosides | Leukemia, Myeloid, Acute | Life Sciences | Antibodies, Monoclonal, Humanized | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
by Decroocq, Justine and Itzykson, Raphaël and Vigouroux, Stéphane and Michallet, Mauricette and Yakoub‐Agha, Ibrahim and Huynh, Anne and Beckerich, Florence and Suarez, Felipe and Chevallier, Patrice and Nguyen‐Quoc, Stéphanie and Ledoux, Marie‐Pierre and Clement, Laurence and Hicheri, Yosr and Guillerm, Gaëlle and Cornillon, Jérôme and Contentin, Nathalie and Carre, Martin and Maillard, Natacha and Mercier, Mélanie and Mohty, Mohamad and Beguin, Yves and Bourhis, Jean‐Henri and Charbonnier, Amandine and Dauriac, Charles and Bay, Jacques‐Olivier and Blaise, Didier and Deconinck, Eric and Jubert, Charlotte and Raus, Nicole and Peffault de Latour, Regis and Dhedin, Nathalie
American Journal of Hematology, ISSN 0361-8609, 03/2018, Volume 93, Issue 3, pp. 416 - 423
Patients with acute myeloid leukemia (AML) in relapse or refractory to induction therapy have a dismal prognosis. Allogeneic hematopoietic stem cell... 
DONOR LYMPHOCYTE TRANSFUSION | COMPLETE REMISSION | PROGNOSTIC-FACTORS | BONE-MARROW-TRANSPLANTATION | HIGH-RISK | ACUTE MYELOGENOUS LEUKEMIA | 1ST RELAPSE | PRIMARY INDUCTION FAILURE | HEMATOLOGY | VERSUS-HOST-DISEASE | MYELODYSPLASTIC SYNDROME | Myeloablative Agonists - therapeutic use | Recurrence | Whole-Body Irradiation | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Salvage Therapy | Male | Young Adult | Allografts | Adult | Female | Retrospective Studies | Lymphocyte Transfusion | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Survival Rate | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Adolescent | Myeloablative Agonists - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellula
by Decroocq, Justine and Itzykson, Raphaël and Vigouroux, Stéphane and Michallet, Mauricette and Yakoub-Agha, Ibrahim and Huynh, Anne and Beckerich, Florence and Suarez, Felipe and Chevallier, Patrice and Nguyen-Quoc, Stéphanie and Ledoux, Marie-Pierre and Clement, Laurence and Hicheri, Yosr and Guillerm, Gaëlle and Cornillon, Jérôme and Contentin, Nathalie and Carre, Martin and Maillard, Natacha and Mercier, Mélanie and Mohty, Mohamad and Beguin, Yves and Bourhis, Jean-Henri and Charbonnier, Amandine and Dauriac, Charles and Bay, Jacques-Olivier and Blaise, Didier and Deconinck, Eric and Jubert, Charlotte and Raus, Nicole and Peffault de Latour, Regis and Dhedin, Nathalie
American Journal of Hematology, ISSN 0361-8609, 03/2018, Volume 93, Issue 3, pp. 416 - 423
Life Sciences | Hematology | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)
by Reignier, Jean and Boisramé-Helms, Julie and Brisard, Laurent and Lascarrou, Jean-Baptiste and Ait Hssain, Ali and Anguel, Nadia and Argaud, Laurent and Asehnoune, Karim and Asfar, Pierre and Bellec, Frédéric and Botoc, Vlad and Bretagnol, Anne and Bui, Hoang-Nam and Canet, Emmanuel and Da Silva, Daniel and Darmon, Michael and Das, Vincent and Devaquet, Jérôme and Djibre, Michel and Ganster, Frédérique and Garrouste-Orgeas, Maité and Gaudry, Stéphane and Gontier, Olivier and Guérin, Claude and Guidet, Bertrand and Guitton, Christophe and Herbrecht, Jean-Etienne and Lacherade, Jean-Claude and Letocart, Philippe and Martino, Frédéric and Maxime, Virginie and Mercier, Emmanuelle and Mercier, Romain and Mira, Jean-Paul and Nseir, Saad and Piton, Gael and Quenot, Jean-Pierre and Richecoeur, Jack and Rigaud, Jean-Philippe and Robert, René and Rolin, Nathalie and Schwebel, Carole and Sirodot, Michel and Tinturier, François and Thévenin, Didier and Giraudeau, Bruno and Le Gouge, Amélie and Dupont, Hervé and Pierrot, Marc and Beloncle, François and Combaux, Danièle and Winiszewski, Hadrien and Capellier, Gilles and Hilbert, Gilles and Gruson, Didier and Kalfon, Pierre and Souweine, Bertrand and Coupez, Elizabeth and Ricard, Jean-Damien and Messika, Jonathan and Bougerol, François and Declercq, Pierre-Louis and Dargent, Auguste and Large, Audrey and Annane, Djillali and Clair, Bernard and Bonadona, Agnès and Hamidfar, Rebecca and Richard, Christian and Henry-Lagarrigue, Mathieu and Yehia, Ahiem Yehia and Temime, Johanna and Barrailler, Stephanie and Favory, Raphaël and Parmentier-Decrucq, Erika and Jourdain, Mercé and Baboi, Loredana and Simon, Marie and Baudry, Thomas and Monchi, Mehran and Roustan, Jérôme and Bardou, Patrick and Cottereau, Alice and Guiot, Philippe and Brule, Noelle and Landais, Mickael and Roquilly, Antoine and Boulain, Thierry and Benzekri, Dalila and Champigneulle, Benoit and Tahiri, Jalel and Preda, Gabriel and Misset, Benoit and Lemiale, Virginie and Zafrani, Lara and Fartoukh, Muriel and Thiéry, Guillaume and Chatellier, Delphine and Coudroy, Rémi and Chouquer, Renaud and ... and NUTRIREA-2 Trial Investigators and Clinical Research in Intensive Care and Sepsis (CRICS) group
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10116, pp. 133 - 143
Whether the route of early feeding affects outcomes of patients with severe critical illnesses is controversial. We hypothesised that outcomes were better with... 
MORTALITY | SUPPORT | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | SCORE | INTENSIVE-CARE-UNIT | GUIDELINES | PATIENT | INTOLERANCE | CRITICALLY-ILL PATIENTS | FAILURE | Length of Stay | Vasoconstrictor Agents - therapeutic use | Hospital Mortality | Humans | Middle Aged | Male | Treatment Outcome | Enteral Nutrition | Respiration, Artificial | Shock - mortality | Time Factors | Adult | Critical Care | Female | Shock - therapy | Aged | Parenteral Nutrition | Shock - complications | Ventilators | Intensive care | Nutrition | Enteral nutrition | Mortality | Clinical trials | Parenteral nutrition | Ventilation | Adults
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
by Cecile Pautas and Fatiha Merabet and Xavier Thomas and Emmanuel Raffoux and Claude Gardin and Selim Corm and Jean-Henri Bourhis and Oumedaly Reman and Pascal Turlure and Nathalie Contentin and Thierry de Revel and Philippe Rousselot and Claude Preudhomme and Dominique Bordessoule and Pierre Fenaux and Christine Terré and Mauricette Michallet and Hervé Dombret and Sylvie Chevret and Sylvie Castaigne
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 808 - 814
Purpose In patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine. High doses of... 
ADULT PATIENTS | CYTOSINE-ARABINOSIDE | ONCOLOGY-GROUP | ONCOLOGY | COMPETING RISK | FREE SURVIVAL | ACUTE MYELOGENOUS LEUKEMIA | CONSOLIDATION THERAPY | PHASE-3 TRIAL | TRIAL COMPARING IDARUBICIN | 1ST COMPLETE REMISSION | Recurrence | Risk Assessment | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Recombinant Proteins - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Interleukin-2 - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Female | Idarubicin - administration & dosage | Aged | Interleukin-2 - analogs & derivatives | Daunorubicin - administration & dosage | Index Medicus | Life Sciences | Immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Development of a ‘ready-to-use’ tool that includes preventability, for the assessment of adverse drug events in oncology
by Hébert, Guillaume and Netzer, Florence and Kouakou, Sylvain Landry and Lemare, François and Minvielle, Etienne and Assaf, Elias and Bardin, Christophe and Basuyau, Florence and Bedouch, Pierrick and Charlety, Dominique and Contentin, Nathalie and Daouphars, Mikael and Di Fiore, Frédéric and Doucet, Ludovic and Guillemet, Cécile and Joly, Anne-Chrisitine and Joly, Charlotte and Le Bras, Fabien and Leheurteur, Marianne and Lottin, Marion and Lucas, Mélodie and Madelaine, Isabelle and Merle, Véronique and Pons-Kerjean, Nathalie and Remon-Masip, Jordi and Rousseau, Benoit and Rouvet, Jean and Saldana, Caroline and Slimano, Florian and Toffart, Anne-Claire and Tournigand, Christophe and Varin, Remi and Vekhoff, Anne and Verlinde-Carvalho, Muriel and IATRIGGER Working Grp and IATRIGGER Working Group and the IATRIGGER Working Group
International Journal of Clinical Pharmacy, ISSN 2210-7703, 04/2018, Volume 40, Issue 2, pp. 376 - 385
Background Adverse drug events (ADEs) occur frequently in oncology and justify continuous assessment and monitoring. There are several methods for detecting... 
Preventability | Patient cancer care | Oncology | Trigger tool | France | Adverse drug event | Healthcare quality | HOSPITALIZED-PATIENTS | IDENTIFY | QUALITY | GLOBAL TRIGGER TOOL | HARM | PATIENT SAFETY | FEBRILE NEUTROPENIA | CANCER CARE | CLINICAL-PRACTICE GUIDELINE | SURVEILLANCE | PHARMACOLOGY & PHARMACY | Construction standards | Evaluation | Side effects | Hospitals | Construction methods | Tools | Sentences | Criteria | Monitoring | Cancer | Constitution
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights